Remegen Co.,Ltd.(688331),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688331 Remegen Co.,Ltd.

Trading 04-03 13:06:17

145.80

-4.13

-2.75%

High149.92	Low142.66	Vol7.82M
Open145.00	D1 Closing149.93	Amplitude4.84%
Mkt Cap82.23B	Tradable Cap23.77B	Total Shares564.00M
T/O1.14B	T/O Rate4.80%	Tradable Shares163.00M
P/B23.45	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"Remegen Co.,Ltd.","latestPrice":145.8,"timestamp":1775192777000,"preClose":149.93,"halted":0,"volume":7823959,"delay":0,"changeRate":-0.0275,"floatShares":163000000,"shares":564000000,"eps":5.1157,"marketStatus":"Trading","change":-4.13,"latestTime":"04-03 13:06:17","open":145,"high":149.92,"low":142.66,"amount":1142000000,"amplitude":0.0484,"askPrice":145.86,"askSize":1,"bidPrice":145.8,"bidSize":1,"shortable":0,"etf":0,"ttmEps":5.1157,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775199600000},"marketStatusCode":2,"adr":0,"adjPreClose":149.93,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":164.92,"lowLimit":134.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":23.45,"roa":"--","peRate":28.500498,"roe":"24.87%","epsLYR":1.29,"committee":0.45098,"marketValue":82301000000,"turnoverRate":0.048,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-04-08.","hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"REMEGEN","latestPrice":115.2,"timestamp":1775117301010,"preClose":110.4,"halted":0,"volume":9029425,"delay":0,"premium":"-30.61"},"floatMarketCap":23779000000},"requestUrl":"/m/hq/s/688331/wiki","defaultTab":"wiki","newsList":[{"id":"1140369492","title":"China International Capital Corporation Maintains Outperform Rating on REMEGEN, Raises Target Price to HK$133.7","url":"https://stock-news.laohu8.com/highlight/detail?id=1140369492","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140369492?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:52","pubTimestamp":1775184759,"startTime":"0","endTime":"0","summary":"China International Capital Corporation (CICC) has released a research report reiterating its Outperform rating on REMEGEN (09995) and increasing its target price by 26.8% to HK$133.7. This new...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","09995","BK1583","BK1574","688331","LU1969619763.USD","LU2328871848.SGD","LU1064130708.USD","BK1161","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178735170","title":"Lilly's Oral GLP-1 Weight Loss Drug Receives FDA Approval, Offering Daily Pill Alternative to Injections","url":"https://stock-news.laohu8.com/highlight/detail?id=1178735170","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178735170?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:45","pubTimestamp":1775184311,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration (FDA) approved Eli Lilly's oral GLP-1 drug, Foundayo (active ingredient: orforglipron), for market release this Wednesday. This marks a significant milestone for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999018857.SGD","SG9999017495.SGD","LU2112291526.USD","BK4581","LU1983299246.USD","LU2108987350.USD","LU2552382215.SGD","LU2213496289.HKD","LU2089283258.USD","LU0106261372.USD","LU2461242641.AUD","LU1712237335.SGD","IE00BJJMRZ35.SGD","LU2111349929.HKD","LU2360106947.USD","SG9999014914.USD","LU0210536198.USD","SG9999015978.USD","IE0001KFT4U8.USD","LU0203201768.USD","BK4533","LU0256863902.USD","LU0316494557.USD","LU2089984988.USD","LU0385154629.USD","SG9999015986.USD","LU0058720904.USD","SGXZ57979304.SGD","LU1366192091.USD","SG9999015952.SGD","LU0823416689.USD","LU0354030511.USD","LU0943347566.SGD","LU0061475181.USD","LU1551013425.SGD","LU2471134796.USD","LU1868837300.USD","LU1989771016.USD","SG9999014906.USD","LU0823434740.USD","LU1720051108.HKD","LU2023250504.SGD","SG9999015945.SGD","ELIL","LU2089284900.SGD","LU1291159041.SGD","LU2746668461.USD","LU2357305700.SGD","IE0004445015.USD","LU0353189680.USD","LU0417517546.SGD","LU2602419157.SGD","LU1868836914.USD","LU0238689110.USD","LU2462157665.USD","LU1323610961.USD","LU2236285917.USD","LU0203202063.USD","LU2417539215.USD","BK4534","IE00B2B36J28.USD","IE00BN29S564.USD","IE00B1BXHZ80.USD","LU0094547139.USD","IE00BKPKM429.USD","LU0158827781.USD","LU2237443465.HKD","LLII","LU0640476718.USD","LU1267930730.SGD","LU2264538146.SGD","IE00B1XK9C88.USD","LU0882574139.USD","LU1814569148.SGD","LU2237443895.HKD","SGXZ81514606.USD","LU2552382058.USD","LU2087625088.SGD","SG9999001176.SGD","LU0096364046.USD","IE0004445239.USD","BK4007","IE00BJJMRX11.SGD","BK4588","LU2746668974.SGD","LU2168564065.EUR","LU2106854487.HKD","SG9999014898.SGD","LU0823434583.USD","LU1720051017.SGD","LU2211815571.USD","LU0353189763.USD","SGXZ99366536.SGD","LU2468319806.SGD","LU2456880835.USD","LU0109394709.USD","LU0097036916.USD","LU0683600562.USD","LU2471134523.USD","LU2237443382.USD","LU2265009873.SGD","LU0787776722.HKD","LU2552382132.HKD","SG9999014880.SGD","01066","LU2237443622.USD","IE0005OL40V9.USD","LLY","LLYX","LU0889565916.HKD","LU0266013472.USD","LU2361044949.HKD","IE00B7KXQ091.USD","IE00B775H168.HKD","IE00BJLML261.HKD","BK4585","LU2750360997.AUD","SHWGY","LU1551013342.USD","LU2756315318.SGD","LU1629891620.HKD","LU1868836591.USD","LU1057294990.SGD","LU0158827948.USD","IE00BFSS8Q28.SGD","IE00BJJMRY28.SGD","IE00BKDWB100.SGD","LU0466842654.USD","LU0323591593.USD","LU1988902786.USD","IE0002141913.USD","LU2271345857.HKD","LLYZ","BK4516","LU0114720955.EUR","LU0456855351.SGD","LU2324357040.USD","LU1064131342.USD","LU0109391861.USD","LU1280957306.USD","LU1035775433.USD","LU2023251221.USD","LU0820561818.USD","LU2023250330.USD","IE00BFSS7M15.SGD","LU0672654240.SGD","LU1623119135.USD","LU0289739699.SGD","SG9999018865.SGD","BK4599","IE00BJT1NW94.SGD","LU0122379950.USD","LU0256863811.USD","LU1093756168.USD","LU1127390331.HKD","LU2237443978.SGD","IE00B4JS1V06.HKD","LU2237443549.SGD","LU0006306889.USD","LU0320765992.SGD","LU0820561909.HKD","LU0964807845.USD","LU0320765059.SGD","LU1974910355.USD","LU1061106388.HKD","LU0471298777.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","09995","LU2028103732.USD","LU2361044865.SGD","LU2491050071.SGD","LU1868837136.USD","LU2896262040.SGD","IE00BK4W5M84.HKD","LU1917777945.USD","LU0708995401.HKD","LU0471298694.HKD","LU0786609619.USD","LU1069344957.HKD","LU1145028129.USD","LU2756315664.SGD","LU2168563687.JPY","LU2750360641.GBP","LU0234572021.USD","LU0354030438.USD","LU2168564222.USD","LU0225283273.USD","SG9999001176.USD","LU1093756325.SGD","LU0079474960.USD","LU2471134879.HKD","LU0432979614.USD","LU0820562030.AUD","GB00BDT5M118.USD","LU1023059063.AUD","ELIS","LU0198837287.USD","LU2471134952.CNY","SGXZ31699556.SGD","LU1548497426.USD","LU2063271972.USD","LU1232071149.USD","688331","LU1804176565.USD","LU2361045086.USD","LU2491049909.HKD","SGXZ51526630.SGD","LU2168564495.EUR","SG9999013999.USD","LU1868836757.USD","LU2237438978.USD","LU0882574055.USD","LU2491050154.USD","IE00BWXC8680.SGD","IE00BK4W5L77.USD","LU0689472784.USD","LU2168564149.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624522517","title":"BRIEF-Remegen Says NMPA Approves Clinical Trial Of Bispecific Antibody-Drug Conjugate Rc288 For Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2624522517","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624522517?lang=en_us&edition=fundamental","pubTime":"2026-04-01 23:29","pubTimestamp":1775057370,"startTime":"0","endTime":"0","summary":"BRIEF-Remegen Says NMPA Approves Clinical Trial Of Bispecific Antibody-Drug Conjugate Rc288 For InjectionApril 1  - RemeGen Co Ltd 688331.SS:CHINA NMPA APPROVES CLINICAL TRIAL OF BISPECIFIC ANTIBODY-DRUG CONJUGATE  RC288 FOR INJECTIONFurther company coverage: 688331.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","LU1064131003.USD","BK0239","LU1064130708.USD","LU2148510915.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514126","title":"China NMPA approves RemeGen RC288 bispecific ADC Phase I/IIa trial for solid tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514126","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514126?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:29","pubTimestamp":1775053790,"startTime":"0","endTime":"0","summary":"China NMPA cleared RemeGen to start Phase I/IIa trial of bispecific ADC RC288 for injection.Study will test RC288 as monotherapy in locally advanced unresectable or metastatic malignant solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbCMkhz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU2148510915.USD","LU1064130708.USD","688331","LU2488822045.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514194","title":"RemeGen -  China Nmpa Approves Clinical Trial of Bispecific Antibody-Drug Conjugate (Bispecific ADC) Rc288 for Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514194?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:29","pubTimestamp":1775053752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0M3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131003.USD","BK0239","LU1064130708.USD","LU2148510915.USD","LU2488822045.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194246479","title":"Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288","url":"https://stock-news.laohu8.com/highlight/detail?id=1194246479","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194246479?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:50","pubTimestamp":1775033435,"startTime":"0","endTime":"0","summary":"Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","688331","BK4080","LU1969619763.USD","LU2148510915.USD","BK0239","BK1583","LU1064131003.USD","LU2488822045.USD","BK1574","LU2328871848.SGD","09995","LU1064130708.USD","BK4231","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623398317","title":"Vor Bio doses first patient in Phase 3 telitacicept Sjögren’s disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623398317","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623398317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:05","pubTimestamp":1774872347,"startTime":"0","endTime":"0","summary":"Vor Bio dosed first patient in UPSTREAM SjD, a global Phase 3 registrational trial of telitacicept in adults with active primary Sjgren’s disease.Trial targets enrollment of about 250 patients, testing subcutaneous telitacicept versus placebo.Primary endpoint measures change in ESSDAI score at Week 48.RemeGen presented Phase 3 China data in late 2025, reporting statistically significant, clinically meaningful improvements in ESSDAI and ESSPRI.Vor Bio positioned telitacicept as only BAFF/APRIL inhibitor in Phase 3 development for Sjgren’s disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4B8kHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU1064131003.USD","IE00BN0W2V16.EUR","LU2095319765.USD","LU0314104364.USD","688331","LU2148510915.USD","VOR","SG9999014021.USD","BK4139","BK4588","LU2210149790.SGD","BK4585","LU2210150020.SGD","SG9999014013.SGD","NDAQ","LU2488822045.USD","SG9999014039.USD","SG9999014005.SGD","LU1064130708.USD","IE00BGHQF748.EUR","BK4112","IE00BN0W2W23.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623952043","title":"RemeGen Returns to Profitability in 2025; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623952043","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623952043?lang=en_us&edition=fundamental","pubTime":"2026-03-30 13:40","pubTimestamp":1774849219,"startTime":"0","endTime":"0","summary":"RemeGen  posted a profit attributable to owners of 709.7 million yuan for 2025, from a loss of 1.47 billion yuan a year earlier, according to a March 27 Hong Kong bourse filing.The biopharmaceutical company's Hong Kong shares were up nearly 6% in Monday's afternoon trade.Earnings per share came in at 1.29 yuan, compared with a loss per share of 2.73 yuan a year earlier.Revenue rose to 3.24 billion yuan from 1.71 billion yuan in 2024.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1064131003.USD","BK1574","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","BK1583","LU2148510915.USD","BK0239","BK1161","LU1064130708.USD","09995","688331"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1128241186","title":"Insilico Medicine Soars 15% After Announcing $2.75 Billion Partnership with Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=1128241186","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128241186?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:34","pubTimestamp":1774838074,"startTime":"0","endTime":"0","summary":"On March 30th, amidst a broad downturn in A-shares and Hong Kong stocks, innovative drugmakers stood out as a top performer. The Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","BK1583","SG9999014914.USD","SGXZ57979304.SGD","LU1366192091.USD","IE00BK4W5L77.USD","LU0198837287.USD","LU1623119135.USD","LU0158827781.USD","LU1868837136.USD","LU0353189680.USD","LU2552382132.HKD","SG9999015978.USD","LU0823434583.USD","LLYZ","LU0058720904.USD","LU0820562030.AUD","LU0109394709.USD","LU1974910355.USD","LU0471298694.HKD","LU0466842654.USD","LU2112291526.USD","LU2237443978.SGD","IE00B1BXHZ80.USD","LU1917777945.USD","LU2756315664.SGD","LU0882574055.USD","LU2237443549.SGD","LU1127390331.HKD","LU2461242641.AUD","LU1969619763.USD","LU2746668974.SGD","IE00BJJMRY28.SGD","LU0122379950.USD","LU0106261372.USD","LU2552382058.USD","LU1064130708.USD","LU2264538146.SGD","LU2265009873.SGD","IE00BJJMRX11.SGD","SG9999001176.SGD","LU1629891620.HKD","SGXZ81514606.USD","LU2063271972.USD","SG9999015986.USD","IE00B4R5TH58.HKD","ELIS","LU0964807845.USD","LU2089984988.USD","LU1064131003.USD","LU1720051017.SGD","LU1804176565.USD","LU0210536198.USD","LU2361044949.HKD","LU2750360997.AUD","LU1069344957.HKD","LU1093756325.SGD","LU2271345857.HKD","LU0943347566.SGD","IE00B1XK9C88.USD","LU0820561818.USD","IE00BK4W5M84.HKD","LU2237438978.USD","IE00BKDWB100.SGD","LU0234572021.USD","LU1868836591.USD","LU2602419157.SGD","LU0323591593.USD","LU0889565916.HKD","LLII","LU0353189763.USD","IE00BWXC8680.SGD","LU1064131342.USD","LU1868836757.USD","LU2023250504.SGD","LU0683600562.USD","LU1023059063.AUD","LU0238689110.USD","IE00BN29S564.USD","LU2237443382.USD","SG9999018865.SGD","LU0417517546.SGD","ELIL","IE00BJT1NW94.SGD","LU0787776722.HKD","IE0009355771.USD","LU0158827948.USD","SGXZ51526630.SGD","LU0354030511.USD","LU2168564495.EUR","LU1548497426.USD","BK4007","LU1267930730.SGD","LU2746668461.USD","LU1868837300.USD","LU0114720955.EUR","LU1323610961.USD","LU2328871848.SGD","LU2213496289.HKD","LU0320765992.SGD","LU0471298777.SGD","LU0708995401.HKD","LU2491050071.SGD","SG9999014880.SGD","LU2087625088.SGD","SG9999017495.SGD","LU2552382215.SGD","SGXZ31699556.SGD","LU0786609619.USD","LU1983299246.USD","LU2237443895.HKD","LU0320765059.SGD","LU1988902786.USD","LU0289739699.SGD","LU0385154629.USD","LU0823434740.USD","LU2488822045.USD","LU0079474960.USD","LU1551013342.USD","IE00BKPKM429.USD","LU2756315318.SGD","LU2456880835.USD","LU2361045086.USD","BK4588","LU2023251221.USD","LU0316494557.USD","LU2471134523.USD","LU2106854487.HKD","LU0256863811.USD","IE0001KFT4U8.USD","LU2361044865.SGD","BK0239","LU0882574139.USD","LU2324357040.USD","LU1720051108.HKD","IE00BFSS7M15.SGD","SG9999015952.SGD","LU2471134796.USD","LU0820561909.HKD","BK1161","LU0689472784.USD","LU2237443465.HKD","BK4585","LU2471134879.HKD","SGXZ99366536.SGD","SG9999018857.SGD","LU1093756168.USD","LU0203201768.USD","688331","LU0094547139.USD","IE0005OL40V9.USD","LU0354030438.USD","LU0823416689.USD","LU1061106388.HKD","LU2028103732.USD","LU2111349929.HKD","LU2211815571.USD","BK4533","LU1712237335.SGD","SG9999015945.SGD","LU2417539215.USD","IE0004445239.USD","LU2360106947.USD","LU1280957306.USD","LU1989771016.USD","LU0061475181.USD","BK4599","LU2896262040.SGD","SG9999013999.USD","GB00BDT5M118.USD","LU0266013472.USD","BK4534","LU0096364046.USD","LU1868836914.USD","BK4516","LU2148510915.USD","LU2168564149.EUR","LU2491050154.USD","LU2168563687.JPY","LU0432979614.USD","LU0109391861.USD","LU0256863902.USD","LU2236285917.USD","LU0225283273.USD","09995","IE0004445015.USD","IE00BFSS8Q28.SGD","LU0640476718.USD","LU0203202063.USD","LU1551013425.SGD","IE0002141913.USD","LU0672654240.SGD","IE00B775H168.HKD","BK4581","SG9999014906.USD","LU1291159041.SGD","SG9999001176.USD","LU0097036916.USD","520880","LU2089283258.USD","LU1232071149.USD","LU0456855351.SGD","LU1035775433.USD","LU1057294990.SGD","LU2491049909.HKD","LU2089284900.SGD","LU2023250330.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU1814569148.SGD","IE00BJLML261.HKD","LU2108987350.USD","BK1574","IE00B4JS1V06.HKD","SG9999014898.SGD","IE00B2B36J28.USD","LLY","LU2237443622.USD","IE00B7KXQ091.USD","LU1145028129.USD","LU0006306889.USD","LU2471134952.CNY","LU2462157665.USD","LU2168564065.EUR","LLYX","LU2750360641.GBP","LU2168564222.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180728828","title":"REMEGEN Shares Surge Over 8% Following Strong Annual Results Showing Profit Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1180728828","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180728828?lang=en_us&edition=fundamental","pubTime":"2026-03-30 10:00","pubTimestamp":1774836032,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) rose more than 8% in Hong Kong trading. At the time of writing, the stock was up 8.13% to HK$101.8, with a turnover of HK$284 million. The company reported its 2025 annual results,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK4585","BK4588","LU2488822045.USD","VXUS","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","LU1064131003.USD","BK0239","688331","BK1161","LU1064130708.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622087542","title":"BRIEF-Remegen Posts FY Revenue RMB 3,241.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622087542","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622087542?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:31","pubTimestamp":1774625480,"startTime":"0","endTime":"0","summary":"BRIEF-Remegen Posts FY Revenue RMB 3,241.6 MillionMarch 27 (Reuters) - RemeGen Co Ltd 688331.SS:REMEGEN FY REVENUE RMB 3,241.6 MILLIONPROFIT FOR THE YEAR ATTRIBUTABLE RMB709.7 MILLIONFurther company coverage: 688331.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nPLX6A8542:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU1064130708.USD","688331","LU2488822045.USD","BK0239","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120460379","title":"Remegen Co.,Ltd. Board Approves Multiple Proposals Including the 2025 General Manager Work Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1120460379","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120460379?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:40","pubTimestamp":1774622431,"startTime":"0","endTime":"0","summary":"On March 27, Remegen Co.,Ltd. announced that its Second Board of Directors, at its 36th meeting, reviewed and passed multiple proposals. These included the \"Proposal on the Company's 2025 General...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","09995","BK1161","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","LU2488822045.USD","688331","LU1064131003.USD","BK0239","LU1969619763.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171218736","title":"REMEGEN Reports Annual Profit of 710 Million Yuan, Turning Around from Prior Year Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1171218736","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171218736?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:10","pubTimestamp":1774620636,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) announced its annual results for the period ending December 31, 2025. The group achieved revenue of RMB 3.242 billion, an increase of 89.55% compared to the previous year. Profit...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU2488822045.USD","BK1583","LU1064131003.USD","LU2328871848.SGD","09995","BK0239","LU2148510915.USD","BK1161","LU1064130708.USD","688331","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133830766","title":"REMEGEN Shares Climb Over 5% as Disitamab Vedotin Gains Fourth Indication Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1133830766","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133830766?lang=en_us&edition=fundamental","pubTime":"2026-03-24 10:50","pubTimestamp":1774320629,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 2.46%, trading at HK$89.50, with a turnover of HK$151 million. REMEGEN issued an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK1583","LU1064131003.USD","688331","LU1064130708.USD","BK1161","LU2488822045.USD","BK0239","09995","BK1574","LU2148510915.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770867","title":"RemeGen wins China NMPA approval for disitamab vedotin in HER2-low breast cancer with liver metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770867","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770867?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:10","pubTimestamp":1774264243,"startTime":"0","endTime":"0","summary":"RemeGen said China’s National Medical Products Administration approved a new indication for disitamab vedotin  to treat HER2-low breast cancer with liver metastases.The indication covers adult patients with unresectable or metastatic disease who have received at least one prior systemic therapy in the metastatic setting or relapsed within 12 months after adjuvant chemotherapy.The approval was supported by results from the Phase III RC48-C012 trial conducted in China.This is the fourth approved indication for disitamab vedotin in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLljydJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1064131003.USD","688331","LU2488822045.USD","LU2148510915.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777015","title":"BRIEF-RemeGen Co Says NMPA Approved New Drug Application For Disitamab Vedotin","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777015","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777015?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:08","pubTimestamp":1774264111,"startTime":"0","endTime":"0","summary":"BRIEF-RemeGen Co Says NMPA Approved New Drug Application For Disitamab VedotinMarch 23 (Reuters) - RemeGen Co Ltd 688331.SS:APPROVAL OF NEW DRUG APPLICATION FOR DISITAMAB VEDOTIN BY NMPAFurther company coverage: 688331.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40A059:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2488822045.USD","BK0239","LU2148510915.USD","688331","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621677705","title":"RemeGen Co Ltd - Approval of New Drug Application for Disitamab Vedotin by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2621677705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621677705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:07","pubTimestamp":1774264076,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40A059:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1064131003.USD","BK0239","688331","LU1064130708.USD","LU2488822045.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117231507","title":"Remegen's ADC Therapy Disitamab Vedotin Secures Approval for New Breast Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1117231507","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117231507?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:52","pubTimestamp":1774255945,"startTime":"0","endTime":"0","summary":"Remegen Co., Ltd. (688331.SH) has announced that it recently obtained a drug registration certificate from the National Medical Products Administration. The new indication application for disitamab...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","BK1161","LU2148510915.USD","BK0239","LU2328871848.SGD","BK1574","BK1583","LU2488822045.USD","LU1064131003.USD","688331","LU1064130708.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160237968","title":"Revised title","url":"https://stock-news.laohu8.com/highlight/detail?id=1160237968","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160237968?lang=en_us&edition=fundamental","pubTime":"2026-03-18 10:16","pubTimestamp":1773800188,"startTime":"0","endTime":"0","summary":"Hong Kong Stock Movement | REMEGEN (09995) Rises Nearly 8% Again as Multiple Original Research Findings on Disitamab Vedotin Presented at 2026 EAU","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK1583","LU1064131003.USD","688331","LU1064130708.USD","VXUS","BK4588","BK1161","LU2488822045.USD","BK4585","BK0239","09995","BK1574","LU2148510915.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620044255","title":"RemeGen to Hold Board Meeting to Approve Annual Results and Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620044255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620044255?lang=en_us&edition=fundamental","pubTime":"2026-03-17 16:32","pubTimestamp":1773736379,"startTime":"0","endTime":"0","summary":"RemeGen will hold a board meeting on March 27, 2026 to consider and approve its annual results for the year ended December 31, 2025. The board will also consider the payment of dividends.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RemeGen Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL5Hw7vp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0239","688331"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","stockEarnings":[{"period":"1week","weight":0.2834},{"period":"1month","weight":0.6389},{"period":"3month","weight":0.9274},{"period":"6month","weight":0.2828},{"period":"1year","weight":2.3768},{"period":"ytd","weight":0.9274}],"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","perCapita":"9343股","boardName":"医药制造业","registeredCapital":"56447万元","compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0493},{"period":"3month","weight":-0.0125},{"period":"6month","weight":0.0094},{"period":"1year","weight":0.1699},{"period":"ytd","weight":-0.0125}],"survey":"　　荣昌生物制药(烟台)股份有限公司的主营业务是研发、生产和销售医药产品、诊断试剂产品。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC148、RC278、RC288。","serverTime":1775192781908,"listedPrice":48,"stockholders":"17456人(较上一季度增加4.94%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Remegen Co.,Ltd.(688331),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Remegen Co.,Ltd.(688331) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Remegen Co.,Ltd.,688331,Remegen Co.,Ltd.股票,Remegen Co.,Ltd.股票老虎,Remegen Co.,Ltd.股票老虎国际,Remegen Co.,Ltd.行情,Remegen Co.,Ltd.股票行情,Remegen Co.,Ltd.股价,Remegen Co.,Ltd.股市,Remegen Co.,Ltd.股票价格,Remegen Co.,Ltd.股票交易,Remegen Co.,Ltd.股票购买,Remegen Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Remegen Co.,Ltd.(688331),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Remegen Co.,Ltd.(688331) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction